Your browser is no longer supported. Please, upgrade your browser.
Settings
CRDL [NASD]
Cardiol Therapeutics Inc.
Index- P/E- EPS (ttm)-0.90 Insider Own9.83% Shs Outstand43.17M Perf Week-8.80%
Market Cap159.33M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float38.57M Perf Month-22.75%
Income-35.00M PEG- EPS next Q- Inst Own9.78% Short Float0.61% Perf Quarter-48.43%
Sales0.08M P/S2023.03 EPS this Y-30.50% Inst Trans- Short Ratio0.24 Perf Half Y-26.77%
Book/sh0.67 P/B2.94 EPS next Y- ROA-130.00% Target Price- Perf Year2.34%
Cash/sh0.35 P/C5.55 EPS next 5Y- ROE-145.40% 52W Range1.82 - 4.96 Perf YTD-9.63%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-60.28% Beta-
Dividend %- Quick Ratio12.00 Sales past 5Y- Gross Margin- 52W Low8.24% ATR0.24
Employees14 Current Ratio12.00 Sales Q/Q- Oper. Margin- RSI (14)32.97 Volatility10.20% 8.88%
OptionableYes Debt/Eq0.01 EPS Q/Q-71.00% Profit Margin- Rel Volume0.76 Prev Close2.05
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume977.37K Price1.97
Recom- SMA20-12.62% SMA50-39.73% SMA200-35.62% Volume739,015 Change-3.90%
Nov-05-21 09:18AM  
Nov-04-21 08:52AM  
Nov-03-21 08:36AM  
Nov-02-21 04:04PM  
Oct-25-21 07:27AM  
Oct-18-21 07:27AM  
Sep-16-21 07:27AM  
Sep-10-21 04:33PM  
Sep-07-21 07:27AM  
Aug-24-21 07:27AM  
Aug-19-21 06:52AM  
Cardiol Therapeutics Inc., a clinical-stage biotechnology company, focuses on the research and development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, an ultra-pure and high concentration cannabidiol oral formulation for the treatment of in hospitalized COVID-19 patients with a prior history of risk factors for CVD; and has completed phase I clinical trials for the treatment of acute myocarditis and other inflammatory heart disease. The company is also developing a proprietary subcutaneous formulation of cannabidiol to achieve higher bioavailability for the treatment chronic heart failure. In addition, it develops proprietary nanotechnology to enable the distribution of water insoluble drugs within the blood circulation, enhance pharmacokinetics, and facilitate drug accumulation in the failing heart. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.